Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 11
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Solved the enigma of pediatric severe acute hepatitis of unknown origin?

  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
  • Rando-Segura, Ariadna|||0000-0003-4555-7286
  • Quer, Josep|||0000-0003-0014-084X
Hepatitis is an inflammation of the liver whose etiology is very heterogeneous. The most common cause of hepatitis is viral infections from hepatotropic viruses, including hepatitis A, B, C, D and E. However, other factors such as infections from other agents, metabolic disorders, or autoimmune reactions can also contribute to hepatitis, albeit to a lesser extent. On April 5, 2022, the United Kingdom Health Security Agency alerted the World Health Organization (WHO) on the increased incidence of severe acute hepatitis of unknown causes (not A-E) in previously healthy young children, with symptoms of liver failure that in some cases required liver transplantation. By July 2022, 1,296 cases were reported in 37 countries. Acute hepatitis of unknown causes is not an exceptional phenomenon: in fact, it represents more than 30% of cases of acute hepatitis in children, however in the present instance the large proportion of severe cases was surprising and alarming (6% of liver transplants and almost 3% mortality). Multiple hypotheses have been proposed to explain the etiology of such higher proportion of acute hepatitis, including their co-occurrence in the context of COVID-19 pandemic. This is a review of the history of a clinical threat that has put in check a world health care system highly sensitized by the current COVID-19 pandemics, and that it looks like has ended with the arguments that the severe acute pediatric hepatitis is caused by Adeno-associated virus 2 (AAV2) infection associated with a coinfection with a helper virus (human Adenovirus HAdV or human herpesvirus 6) in susceptible children carrying HLA-class II antigen HLA-DRB1*04:01.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Inspecting the Ribozyme Region of Hepatitis Delta Virus Genotype 1: Conservation and Variability

  • Pacín Ruíz, Beatriz
  • Tabernero Caellas, David
  • Sopena Santisteve, Sara
  • Garcia Garcia, Selene
  • Casillas Gomez, Rosario
  • Najarro Centeno, Adrián
  • Aldama Bañares, Unai
  • Palom Agusti, Adriana
  • Galan González, Anna
  • Vila Salvador, Marta
  • Riveiro Barciela, Maria del Mar
  • Quer Sivila, Josep
  • Rodríguez Frias, Francisco
  • Rando Segura, Ariadna
  • Gregori Font, Josep
  • Cortese, Maria Francesca
  • Buti Ferret, Maria
Gene silencing; Quasispecies; Ribozyme, Silenciament gènic; Quasiespècie; Ribozima, Silenciamiento de genes; Cuasiespecies; Ribozima, The hepatitis delta virus (HDV) genome has an autocatalytic region called the ribozyme, which is essential for viral replication. The aim of this study was to use next-generation sequencing (NGS) to analyze the ribozyme quasispecies (QS) in order to study its evolution and identify highly conserved regions potentially suitable for a gene-silencing strategy. HDV RNA was extracted from 2 longitudinal samples of chronic HDV patients and the ribozyme (nucleotide, nt 688–771) was analyzed using NGS. QS conservation, variability and genetic distance were analyzed. Mutations were identified by aligning sequences with their specific genotype consensus. The main relevant mutations were tested in vitro. The ribozyme was conserved overall, with a hyper-conserved region between nt 715–745. No difference in QS was observed over time. The most variable region was between nt 739–769. Thirteen mutations were observed, with three showing a higher frequency: T23C, T69C and C64 deletion. This last strongly reduced HDV replication by more than 1 log in vitro. HDV Ribozyme QS was generally highly conserved and was maintained during follow-up. The most conserved portion may be a valuable target for a gene-silencing strategy. The presence of the C64 deletion may strongly impair viral replication, as it is a potential mechanism of viral persistence., This research was funded by Institute of Health Carlos III, grant number PI20/01692 and co-financed by the European Regional Development Fund (ERDF), and by the European Regional Development Fund (ERDF)- Ministry of Economy, Industry and Competitiveness, grantRTI2018-101936-B-I00.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Implementation of anti-HDV reflex testing among HBsAg-positive individuals increases testing for hepatitis D

  • Palom Agusti, Adriana
  • Vico Romero, Judit
  • Pacín Ruíz, Beatriz
  • Vargas Accarino, Elena
  • Barreira Diaz, Ana
  • Rodríguez Frias, Francisco
  • Riveiro Barciela, Maria del Mar
  • Esteban Mur, Rafael
  • Rando Segura, Ariadna
  • Buti Ferret, Maria
Chronic hepatitis D; Anti-HDV screening; HDV diagnosis, Hepatitis crònica D; Cribatge anti-HDV; Diagnòstic de HDV, Hepatitis crónica D; Cribado anti-HDV; Diagnóstico de HDV, Background & Aims Although EASL guidelines recommend anti-HDV testing in all HBsAg-positive individuals, HDV infection remains an underdiagnosed condition. We describe the impact of an HDV screening program by reflex anti-HDV testing in all HBsAg-positive samples and compare the results before and after its implementation. Methods In total, 2,236 HBsAg-positive determinations were included from January 2018 to December 2021. Only the first sample from each participant was evaluated: 1,492 samples before reflex anti-HDV testing (2018–2020) and 744 samples after (2021). Demographic and clinical characteristics of anti-HDV-positive patients were collected. Results Before reflex testing, anti-HDV had been tested in 7.6% (114/1492) of HBsAg-positive individuals: 23% (91/390) attended in an academic hospital and only 2% (23/1,102) in primary care centres. After reflex testing was established, 93% (691/744) of HBsAg-positive cases were evaluated for anti-HDV: 91% (533/586) in the academic hospital and 100% (158/158) in primary care. The anti-HDV-positive prevalence was similar before and after reflex testing: 9.6% (11/114) and 8.1% (56/691), respectively. However, the absolute number of anti-HDV-positive patients increased. Most anti-HDV-positive patients were young, HBeAg-negative, Caucasian males. HDV-RNA was detectable in 35 (65%) of 54 tested, HBV-DNA was undetectable in 64%, and alanine aminotransferase levels were normal in 48%. Conclusions Anti-HDV reflex testing quintupled the absolute number of diagnoses of chronic hepatitis D infection. Before the reflex test, a large percentage of HBsAg-positive individuals had not undergone any anti-HDV determination. Implementation of reflex testing increases the diagnosis of patients with chronic hepatitis D., This study received support in part from the Instituto de Salud Carlos III (PI20/01692).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

ACE Score Identifies HBeAg-negative Inactive Carriers at a Single-point Evaluation, Regardless of HBV Genotype

  • Roade Tato, Maria Luisa
  • Riveiro Barciela, Maria del Mar
  • Palom Agusti, Adriana
  • Rodríguez Frias, Francisco
  • Bes Maijo, Marta
  • Salcedo Allende, Maria Teresa
  • Casillas Gomez, Rosario
  • Vargas Accarino, Elena
  • Tabernero Caellas, David
  • Sauleda Oliveras, Silvia
  • Esteban Mur, Rafael
  • Rando Segura, Ariadna
  • Buti Ferret, Maria
HBV DNA; Hepatitis B virus; Inactive carrier, ADN del VHB; Virus de la hepatitis B; Portador inactivo, ADN del VHB; Virus de l'hepatitis B; Portador inactiu, Background and Aims Hepatitis B virus (HBV) biomarkers have been used for a better categorization of patients, even though the lack of simple algorithms and the impact of genotypes limit their application. Our aim was to assess the usefulness of noninvasive markers for the identification of HBV inactive carriers (ICs) in a single-point evaluation and to design a predictive model for their identification. Methods This retrospective-prospective study included 343 consecutive HBeAg-negative individuals. Clinical, analytical, and virological data were collected, and a liver biopsy was performed if needed. Subjects were classified at the end of follow-up as ICs, chronic hepatitis B and gray zone.A predictive model was constructed, and validated by 1000-bootstrap samples. Results After 39 months of follow-up, 298 subjects were ICs, 36 were chronic hepatitis B CHB, and nine were gray zone. Eighty-nine (25.9%) individuals required a liver biopsy. Baseline HBV DNA hazard ratio (HR) 6.0, p<0.001), HBV core-related antigen (HBcrAg) (HR 6.5, p<0.001), and elastography (HR 4.6, p<0.001) were independently associated with the IC stage. The ACE score (HBV DNA, HBcrAg, elastography), obtained by bootstrapping, yielded an area under the receiver operating characteristics (AUROC) of 0.925 (95% CI: 0.880–0.970, p<0.001) for identification of ICs. The AUROC for genotype D was 0.95, 0.96 for A, 0.90 for E, and 0.88 for H/F. An ACE score of <1 had a positive predictive value of 99.5%, and a score ≤12 points had a diagnostic accuracy of 93.8%. Conclusions Low baseline HBV DNA, HBcrAg, and liver stiffness were independently associated with the IC phase. A score including those variables identified ICs at a single-point evaluation, and might be applied to implement less intensive follow-up strategies., This study received partial financial support from Instituto de Salud Carlos III (PI17/02233 and PI20/01692).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

HBsAg protein composition and clinical outcomes in chronic hepatitis D and variations across HBeAg-negative chronic HBsAg carriers

  • Roade, Luisa
  • Pfefferkorn, Maria
  • Sopena, Sara
  • Bes Maijo, Marta
  • Casillas, Rosario
  • Tabernero, David
  • esteban, rafael
  • Riveiro-Barciela, Mar
  • Palom, Adriana
  • Rando Segura, Ariadna
  • RODRIGUEZ-FRIAS, FRANCISCO
  • Buti Ferret, Maria
HBsAg proteins; Hepatitis D; Surface antigen, Proteínas HBsAg; Hepatitis D; Antígeno de superficie, Proteïnes HBsAg; Hepatitis D; Antigen de superfície, Background & Aims HBsAg proteins are useful to identify HBV inactive carriers (ICs), but data on chronic hepatitis D (CHD) are scarce. This study aimed to describe HBsAg composition in CHD, its changes during the evolution, and the potential association with clinical outcomes. In addition, we assess the composition of HBsAg across different HBV genotypes and validate previous results on HBsAg proteins in an independent HBV cohort. Methods Quantitative HBsAg, medium HBsAg proteins (MHBs), and large HBsAg proteins (LHBs) were measured in two cohorts. The first cohort consisted of patients with CHD. A cross-sectional study of samples from two European institutions (N = 46) was conducted. Outcomes were assessed in a retrospective–prospective study of those patients with a follow-up of >1 year (n = 36), and the longitudinal evolution of HBsAg proteins in those with samples >5 years apart (n = 12) was analysed. The second cohort consisted of patients with HBeAg-negative HBV, and a cross-sectional study was performed (N = 141). Results Forty-one (89%) patients with CHD had detectable HDV-RNA, and the presence of HDV-RNA was associated with higher LHBs proportion (p = 0.010). Baseline MHBs (p = 0.051) and MHBs proportion (p = 0.086) tended to be higher in those developing clinical outcomes (9/36, 25%) after a median follow-up of 5.9 years. Patients in which HDV-RNA became spontaneously undetectable during follow-up (5/31, 16.1%) tended to present lower MHBs proportion (p = 0.085). In the longitudinal study, changes in LHBs proportion were observed (p = 0.041), whereas MHBs proportion remained stable (p = 0.209). Regarding HBV, ICs showed lower LHBs proportion (p = 0.027). LHBs and MHBs differed significantly according to HBV genotype, regardless of the HBV phase. Conclusions Patients with CHD with detectable HDV-RNA presented higher LHBs proportion than those with undetectable HDV-RNA. A trend toward having higher baseline MHBs proportion was observed in patients who developed clinical outcomes or remained with detectable HDV-RNA. This study validates the different HBsAg composition in HBV ICs and reveals the HBV-genotype influence in HBsAg composition. Impact and implications The composition of HBsAg in chronic hepatitis D differs in patients with detectable and undetectable HDV viral load and may help predict the likelihood of achieving undetectable HDV viraemia and the development of clinical events such as decompensation. The composition of the surface antigen is also useful to distinguish inactive carriers of HBV, and it varies according to HBV genotype., This study received partial financial support from Instituto de Salud Carlos III (PI17/02233 and PI20/01692).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

ACE Score Identifies HBeAg-negative Inactive Carriers at a Single-point Evaluation, Regardless of HBV Genotype

  • Roade, Luisa|||0000-0002-8160-9613
  • Riveiro Barciela, Mar|||0000-0001-9309-2052
  • Palom, Adriana|||0000-0002-0130-1302
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
  • Bes, Marta|||0000-0001-6103-072X
  • Rando-Segura, Ariadna|||0000-0003-4555-7286
  • Salcedo, Maria-Teresa|||0000-0002-4822-5060
  • Casillas, Rosario|||0000-0002-6758-6734
  • Vargas-Accarino, Elena|||0000-0002-2521-0368
  • Tabernero, David|||0000-0002-1146-4084
  • Sauleda, Silvia|||0000-0001-7343-9557
  • Esteban, Rafael|||0000-0001-5280-392X
  • Buti, Maria|||0000-0002-0732-3078
Hepatitis B virus (HBV) biomarkers have been used for a better categorization of patients, even though the lack of simple algorithms and the impact of genotypes limit their application. Our aim was to assess the usefulness of noninvasive markers for the identification of HBV inactive carriers (ICs) in a single-point evaluation and to design a predictive model for their identification. This retrospective-prospective study included 343 consecutive HBeAg-negative individuals. Clinical, analytical, and virological data were collected, and a liver biopsy was performed if needed. Subjects were classified at the end of follow-up as ICs, chronic hepatitis B and gray zone.A predictive model was constructed, and validated by 1000-bootstrap samples. After 39 months of follow-up, 298 subjects were ICs, 36 were chronic hepatitis B CHB, and nine were gray zone. Eighty-nine (25.9%) individuals required a liver biopsy. Baseline HBV DNA hazard ratio (HR) 6.0, p <0.001), HBV core-related antigen (HBcrAg) (HR 6.5, p <0.001), and elastography (HR 4.6, p <0.001) were independently associated with the IC stage. The ACE score (HBV DNA, HBcrAg, elastography), obtained by bootstrapping, yielded an area under the receiver operating characteristics (AUROC) of 0.925 (95% CI: 0.880-0.970, p <0.001) for identification of ICs. The AUROC for genotype D was 0.95, 0.96 for A, 0.90 for E, and 0.88 for H/F. An ACE score of <1 had a positive predictive value of 99.5%, and a score ≤12 points had a diagnostic accuracy of 93.8%. Low baseline HBV DNA, HBcrAg, and liver stiffness were independently associated with the IC phase. A score including those variables identified ICs at a single-point evaluation, and might be applied to implement less intensive follow-up strategies.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Implementation of anti-HDV reflex testing among HBsAg-positive individuals increases testing for hepatitis D

  • Palom, Adriana|||0000-0002-0130-1302
  • Rando-Segura, Ariadna|||0000-0003-4555-7286
  • Vico, Judit
  • Pacín Ruiz, Beatriz|||0000-0001-8718-6589
  • Vargas, Elena
  • Barreira-Diaz, Ana|||0000-0002-4368-8939
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
  • Riveiro Barciela, Mar|||0000-0001-9309-2052
  • Esteban, Rafael|||0000-0001-5280-392X
  • Buti, Maria|||0000-0002-0732-3078
Although EASL guidelines recommend anti-HDV testing in all HBsAg-positive individuals, HDV infection remains an underdiagnosed condition. We describe the impact of an HDV screening program by reflex anti-HDV testing in all HBsAg-positive samples and compare the results before and after its implementation. In total, 2,236 HBsAg-positive determinations were included from January 2018 to December 2021. Only the first sample from each participant was evaluated: 1,492 samples before reflex anti-HDV testing (2018-2020) and 744 samples after (2021). Demographic and clinical characteristics of anti-HDV-positive patients were collected. Before reflex testing, anti-HDV had been tested in 7.6% (114/1492) of HBsAg-positive individuals: 23% (91/390) attended in an academic hospital and only 2% (23/1,102) in primary care centres. After reflex testing was established, 93% (691/744) of HBsAg-positive cases were evaluated for anti-HDV: 91% (533/586) in the academic hospital and 100% (158/158) in primary care. The anti-HDV-positive prevalence was similar before and after reflex testing: 9.6% (11/114) and 8.1% (56/691), respectively. However, the absolute number of anti-HDV-positive patients increased. Most anti-HDV-positive patients were young, HBeAg-negative, Caucasian males. HDV-RNA was detectable in 35 (65%) of 54 tested, HBV-DNA was undetectable in 64%, and alanine aminotransferase levels were normal in 48%. Anti-HDV reflex testing quintupled the absolute number of diagnoses of chronic hepatitis D infection. Before the reflex test, a large percentage of HBsAg-positive individuals had not undergone any anti-HDV determination. Implementation of reflex testing increases the diagnosis of patients with chronic hepatitis D. Chronic hepatitis delta (CHD) is a viral disease caused by HDV, which requires the presence of HBV to propagate. HDV infection can cause rapid progression to cirrhosis, among other severe complications. The prevalence of CHD worldwide is controversial, and the infection often goes unrecognised, mainly because of unawareness among physicians. Use of reflex testing in other viral hepatitis has proven to increase detection and linking-to-care of infected patients. Implementation of anti-HDV testing in all HBsAg-positive patients has led to a 5-fold increase in the number of HDV diagnoses in an academic hospital and primary care centres.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

HBsAg protein composition and clinical outcomes in chronic hepatitis D and variations across HBeAg-negative chronic HBsAg carriers

  • Roade, Luisa
  • Pfefferkorn, Maria
  • Sopena, Sara
  • Bes Maijo, Marta
  • Casillas, Rosario
  • Tabernero, David
  • esteban, rafael
  • Riveiro-Barciela, Mar
  • Palom, Adriana
  • Rando Segura, Ariadna
  • RODRIGUEZ-FRIAS, FRANCISCO
  • Buti Ferret, Maria
HBsAg proteins; Hepatitis D; Surface antigen, Proteínas HBsAg; Hepatitis D; Antígeno de superficie, Proteïnes HBsAg; Hepatitis D; Antigen de superfície, Background & Aims HBsAg proteins are useful to identify HBV inactive carriers (ICs), but data on chronic hepatitis D (CHD) are scarce. This study aimed to describe HBsAg composition in CHD, its changes during the evolution, and the potential association with clinical outcomes. In addition, we assess the composition of HBsAg across different HBV genotypes and validate previous results on HBsAg proteins in an independent HBV cohort. Methods Quantitative HBsAg, medium HBsAg proteins (MHBs), and large HBsAg proteins (LHBs) were measured in two cohorts. The first cohort consisted of patients with CHD. A cross-sectional study of samples from two European institutions (N = 46) was conducted. Outcomes were assessed in a retrospective–prospective study of those patients with a follow-up of >1 year (n = 36), and the longitudinal evolution of HBsAg proteins in those with samples >5 years apart (n = 12) was analysed. The second cohort consisted of patients with HBeAg-negative HBV, and a cross-sectional study was performed (N = 141). Results Forty-one (89%) patients with CHD had detectable HDV-RNA, and the presence of HDV-RNA was associated with higher LHBs proportion (p = 0.010). Baseline MHBs (p = 0.051) and MHBs proportion (p = 0.086) tended to be higher in those developing clinical outcomes (9/36, 25%) after a median follow-up of 5.9 years. Patients in which HDV-RNA became spontaneously undetectable during follow-up (5/31, 16.1%) tended to present lower MHBs proportion (p = 0.085). In the longitudinal study, changes in LHBs proportion were observed (p = 0.041), whereas MHBs proportion remained stable (p = 0.209). Regarding HBV, ICs showed lower LHBs proportion (p = 0.027). LHBs and MHBs differed significantly according to HBV genotype, regardless of the HBV phase. Conclusions Patients with CHD with detectable HDV-RNA presented higher LHBs proportion than those with undetectable HDV-RNA. A trend toward having higher baseline MHBs proportion was observed in patients who developed clinical outcomes or remained with detectable HDV-RNA. This study validates the different HBsAg composition in HBV ICs and reveals the HBV-genotype influence in HBsAg composition. Impact and implications The composition of HBsAg in chronic hepatitis D differs in patients with detectable and undetectable HDV viral load and may help predict the likelihood of achieving undetectable HDV viraemia and the development of clinical events such as decompensation. The composition of the surface antigen is also useful to distinguish inactive carriers of HBV, and it varies according to HBV genotype., This study received partial financial support from Instituto de Salud Carlos III (PI17/02233 and PI20/01692).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

ACE Score Identifies HBeAg-negative Inactive Carriers at a Single-point Evaluation, Regardless of HBV Genotype

  • Roade Tato, Maria Luisa
  • Riveiro Barciela, Maria del Mar
  • Palom Agusti, Adriana
  • Rodríguez Frias, Francisco
  • Bes Maijo, Marta
  • Salcedo Allende, Maria Teresa
  • Casillas Gomez, Rosario
  • Vargas Accarino, Elena
  • Tabernero, David
  • Sauleda Oliveras, Silvia
  • Esteban Mur, Rafael
  • Rando Segura, Ariadna
  • Buti Ferret, Maria
HBV DNA; Hepatitis B virus; Inactive carrier, ADN del VHB; Virus de la hepatitis B; Portador inactivo, ADN del VHB; Virus de l'hepatitis B; Portador inactiu, Background and Aims Hepatitis B virus (HBV) biomarkers have been used for a better categorization of patients, even though the lack of simple algorithms and the impact of genotypes limit their application. Our aim was to assess the usefulness of noninvasive markers for the identification of HBV inactive carriers (ICs) in a single-point evaluation and to design a predictive model for their identification. Methods This retrospective-prospective study included 343 consecutive HBeAg-negative individuals. Clinical, analytical, and virological data were collected, and a liver biopsy was performed if needed. Subjects were classified at the end of follow-up as ICs, chronic hepatitis B and gray zone.A predictive model was constructed, and validated by 1000-bootstrap samples. Results After 39 months of follow-up, 298 subjects were ICs, 36 were chronic hepatitis B CHB, and nine were gray zone. Eighty-nine (25.9%) individuals required a liver biopsy. Baseline HBV DNA hazard ratio (HR) 6.0, p<0.001), HBV core-related antigen (HBcrAg) (HR 6.5, p<0.001), and elastography (HR 4.6, p<0.001) were independently associated with the IC stage. The ACE score (HBV DNA, HBcrAg, elastography), obtained by bootstrapping, yielded an area under the receiver operating characteristics (AUROC) of 0.925 (95% CI: 0.880–0.970, p<0.001) for identification of ICs. The AUROC for genotype D was 0.95, 0.96 for A, 0.90 for E, and 0.88 for H/F. An ACE score of <1 had a positive predictive value of 99.5%, and a score ≤12 points had a diagnostic accuracy of 93.8%. Conclusions Low baseline HBV DNA, HBcrAg, and liver stiffness were independently associated with the IC phase. A score including those variables identified ICs at a single-point evaluation, and might be applied to implement less intensive follow-up strategies., This study received partial financial support from Instituto de Salud Carlos III (PI17/02233 and PI20/01692).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Implementation of anti-HDV reflex testing among HBsAg-positive individuals increases testing for hepatitis D

  • Palom Agusti, Adriana
  • Vico Romero, Judit
  • Pacín Ruíz, Beatriz
  • Vargas Accarino, Elena
  • Barreira Diaz, Ana
  • Rodríguez Frias, Francisco
  • Riveiro Barciela, Maria del Mar
  • Esteban Mur, Rafael
  • Rando Segura, Ariadna
  • Buti Ferret, Maria
Chronic hepatitis D; Anti-HDV screening; HDV diagnosis, Hepatitis crònica D; Cribatge anti-HDV; Diagnòstic de HDV, Hepatitis crónica D; Cribado anti-HDV; Diagnóstico de HDV, Background & Aims Although EASL guidelines recommend anti-HDV testing in all HBsAg-positive individuals, HDV infection remains an underdiagnosed condition. We describe the impact of an HDV screening program by reflex anti-HDV testing in all HBsAg-positive samples and compare the results before and after its implementation. Methods In total, 2,236 HBsAg-positive determinations were included from January 2018 to December 2021. Only the first sample from each participant was evaluated: 1,492 samples before reflex anti-HDV testing (2018–2020) and 744 samples after (2021). Demographic and clinical characteristics of anti-HDV-positive patients were collected. Results Before reflex testing, anti-HDV had been tested in 7.6% (114/1492) of HBsAg-positive individuals: 23% (91/390) attended in an academic hospital and only 2% (23/1,102) in primary care centres. After reflex testing was established, 93% (691/744) of HBsAg-positive cases were evaluated for anti-HDV: 91% (533/586) in the academic hospital and 100% (158/158) in primary care. The anti-HDV-positive prevalence was similar before and after reflex testing: 9.6% (11/114) and 8.1% (56/691), respectively. However, the absolute number of anti-HDV-positive patients increased. Most anti-HDV-positive patients were young, HBeAg-negative, Caucasian males. HDV-RNA was detectable in 35 (65%) of 54 tested, HBV-DNA was undetectable in 64%, and alanine aminotransferase levels were normal in 48%. Conclusions Anti-HDV reflex testing quintupled the absolute number of diagnoses of chronic hepatitis D infection. Before the reflex test, a large percentage of HBsAg-positive individuals had not undergone any anti-HDV determination. Implementation of reflex testing increases the diagnosis of patients with chronic hepatitis D., This study received support in part from the Instituto de Salud Carlos III (PI20/01692).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Inspecting the Ribozyme Region of Hepatitis Delta Virus Genotype 1: Conservation and Variability

  • Pacín Ruíz, Beatriz
  • Tabernero, David
  • Sopena Santisteve, Sara
  • Garcia Garcia, Selene
  • Casillas Gomez, Rosario
  • Najarro Centeno, Adrián
  • Aldama Bañares, Unai
  • Palom Agusti, Adriana
  • Galan González, Anna
  • Vila Salvador, Marta
  • Riveiro Barciela, Maria del Mar
  • Quer Sivila, Josep
  • Rodríguez Frias, Francisco
  • Rando Segura, Ariadna
  • Gregori Font, Josep
  • Cortese, Maria Francesca
  • Buti Ferret, Maria
Gene silencing; Quasispecies; Ribozyme, Silenciament gènic; Quasiespècie; Ribozima, Silenciamiento de genes; Cuasiespecies; Ribozima, The hepatitis delta virus (HDV) genome has an autocatalytic region called the ribozyme, which is essential for viral replication. The aim of this study was to use next-generation sequencing (NGS) to analyze the ribozyme quasispecies (QS) in order to study its evolution and identify highly conserved regions potentially suitable for a gene-silencing strategy. HDV RNA was extracted from 2 longitudinal samples of chronic HDV patients and the ribozyme (nucleotide, nt 688–771) was analyzed using NGS. QS conservation, variability and genetic distance were analyzed. Mutations were identified by aligning sequences with their specific genotype consensus. The main relevant mutations were tested in vitro. The ribozyme was conserved overall, with a hyper-conserved region between nt 715–745. No difference in QS was observed over time. The most variable region was between nt 739–769. Thirteen mutations were observed, with three showing a higher frequency: T23C, T69C and C64 deletion. This last strongly reduced HDV replication by more than 1 log in vitro. HDV Ribozyme QS was generally highly conserved and was maintained during follow-up. The most conserved portion may be a valuable target for a gene-silencing strategy. The presence of the C64 deletion may strongly impair viral replication, as it is a potential mechanism of viral persistence., This research was funded by Institute of Health Carlos III, grant number PI20/01692 and co-financed by the European Regional Development Fund (ERDF), and by the European Regional Development Fund (ERDF)- Ministry of Economy, Industry and Competitiveness, grantRTI2018-101936-B-I00.